Osteonecrosis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Osteonecrosis – Pipeline Review, H2 2019’, provides an overview of the Osteonecrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteonecrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”


– The report provides a snapshot of the global therapeutic landscape of Osteonecrosis

– The report reviews pipeline therapeutics for Osteonecrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Osteonecrosis therapeutics and enlists all their major and minor projects

– The report assesses Osteonecrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Osteonecrosis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteonecrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteonecrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Ankasa Regenerative Therapeutics Inc

Enzo Biochem Inc

K-Stemcell Co Ltd

Regenerative Arthritis & Bone Medicine Inc


Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Osteonecrosis - Overview

Osteonecrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Osteonecrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteonecrosis - Companies Involved in Therapeutics Development

Bone Therapeutics SA

Enzo Biochem Inc

K-Stemcell Co Ltd

Osteonecrosis - Drug Profiles

ALLOB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LWnt-3a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PREOB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology, Oncology and Cardiovascular Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Osteonecrosis - Dormant Projects

Osteonecrosis - Product Development Milestones

Featured News & Press Releases

Jun 08, 2017: Bone Therapeutics: completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB

Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

Jun 08, 2016: Bone Therapeutics demonstrates superiority of PREOB in Phase IIB osteonecrosis study presented at EULAR

May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study

Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB

Nov 07, 2013: Bone Therapeutics' pivotal phase III osteonecrosis trial with PREOB hits a new milestone

Jan 28, 2013: Bone Therapeutics Raises €1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy

Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study




Secondary Research

Primary Research

Expert Panel Validation

Contact Us


List of Tables

“List of Tables

Number of Products under Development for Osteonecrosis, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Osteonecrosis – Pipeline by Ankasa Regenerative Therapeutics Inc, H2 2019

Osteonecrosis – Pipeline by Enzo Biochem Inc, H2 2019

Osteonecrosis – Pipeline by K-Stemcell Co Ltd, H2 2019

Osteonecrosis – Pipeline by Regenerative Arthritis & Bone Medicine Inc, H2 2019

Osteonecrosis – Pipeline by Xcelia, H2 2019

Osteonecrosis – Dormant Projects, H2 2019

Osteonecrosis – Discontinued Products, H2 2019”


Discounts available for multiple report purchases.

+44 (0) 161 359 5414

Saved reports